SIRT1 and neoplasm: As expected from the in vitro results, a reduced tumor burden in KrasG12D/+;Sirt1co/co mice treated with cisplatin or erlotinib compared with the age-matched KRASG12D/+;Sirt1+/+ mice, mice in each single drug treatment group, and KrasG12D/+;Sirt1co/co mice was observed using 18F-FDG PET/CT imaging and calculation of lung SUVmax values (Fig. 7B, C).